Reported resultsCompany-reported
What was reported
SOLANA BEACH, CA, May 13, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗
What the evidence supports
ClearPoint Neuro published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $12.1 million | “• Reported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025;” Mentions: revenue |
| $2.3 million | “• Reported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025;” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineClearPoint Neuro Reports First Quarter 2026 ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗
Press release lead paragraphSOLANA BEACH, CA, May 13, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗
Amount stated in press release• Reported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025;U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 13, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
ClearPoint Neuro Reports First Quarter 2026 Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.